SCHEMBL2913617

SCHEMBL2913617

CN(C)S(=O)(=O)N1CCN(Cc2ccc(C(N)=O)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ALDH1A1 P00352 6/20 0.46
KDM4E B2RXH2 4/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX15 P16050 1/20 0.46
ICAM1 P05362 1/20 0.46
LMNA P02545 2/20 0.46
LSS P48449 2/20 0.45
USP2 O75604 1/20 0.45
MAPK1 P28482 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30576763 0.86 KDM4E (0.60) GAAMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2906362 0.86 KDM4E (0.60) GAAMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2350500 0.84 LMNA (0.57) GAAMEN1KMT2AALDH1A1ICAM1
SCHEMBL13595099 0.82 MEN1 (0.60) MEN1KMT2AALDH1A1LMNA
SCHEMBL2912901 0.82 GAA (0.48) GAAMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2909352 0.81 KDM4E (0.64) GAASMN1; SMN2ALDH1A1KDM4ECYP1A2
SCHEMBL3916832 0.81 KDM4E (0.49) GAAMEN1KMT2AALDH1A1KDM4E
SCHEMBL30576794 0.81 GAA (0.55) GAAMEN1KMT2AALDH1A1KDM4E
SCHEMBL3926162 0.80 KDM4E (0.50) GAAMEN1KMT2AALDH1A1KDM4E
SCHEMBL2776747 0.79 ALDH1A1 (0.59) GAAMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116829542-A Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salts, preparation method thereof and pharmaceutical composition containing same as active ingredient 韩国化学研究院 2023-09-29 CN disclosed
EP-1940786-B1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LTD (GB) 2010-08-18 EP disclosed
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C ARROW THERAPEUTICS LIMITED (GB) 2008-10-16 US disclosed
EP-1940786-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C Arrow Therapeutics Limited (GB) 2008-07-09 EP disclosed
WO-2007031791-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C NR4A1, NR0B1, NR1H4 GAA 3223/4885MEN1 3163/4885KMT2A 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.